APYIAspyra Inc.
The schedule
- Thu15Oct
Given persistent operating cash flow deficits and stagnant sub-penny quotation, APYI faces an elevated risk of announcing a highly dilutive capital raise to maintain baseline operations from a $0.00 base price.
- Thu5Nov
Expected regulatory notices regarding minimal reporting standards and SEC compliance for sub-penny quotation levels originating from a $0.00 base price.
- Wed25Nov
Expected Q3 2026 financial update, focusing on whether the enterprise value of approximately $6M can be fundamentally justified against persistent operating losses from a $0.00 base price.
- Thu26Nov
- Wed20Jan
A potential formal declaration of strategic alternatives, including a reverse merger, shell acquisition, or asset liquidation, evaluated from a $0.00 base price.
- Thu25Feb
- Thu27May
- Thu26Aug
Past
- Thu27Aug
APYI is expected to release its Q2 2026 earnings, providing critical visibility into its ongoing restructuring and balance sheet viability from a $0.00 base price.